An inflammatory arthritis associated with psoriasis, causing joint pain, stiffness, and swelling.
✦ AI summary
Here's what these sources say about psoriatic arthritis (PsA):
- **Underlying biology**: Research has identified a chemokine called CXCL10, which is regulated by an enzyme called DPPIV, as playing an important role in PsA-related joint inflammation. One study found that DPPIV levels in joint fluid were higher in PsA patients than in osteoarthritis patients, and that DPPIV levels changed after starting methotrexate treatment, suggesting this pathway may relate to how well PsA responds to treatment [9]. Separately, genetic research on psoriasis (including cases with psoriatic arthritis) has identified mutations in a gene called ADAR1 that can cause a specific subtype of psoriasis driven by interferon signaling, and lab studies showed certain targeted drugs could reverse some of these effects [2].
- **Mental health burden**: People with PsA and related rheumatic diseases report high rates of depression, anxiety, sleep problems, fatigue, and difficulty identifying/describing emotions (alexithymia), with anxiety and depression roughly twice as common as in the general population; these psychological symptoms are linked to disease activity and pain levels [5].
- **Cardiovasc
This is an AI-generated summary of the sources below — not medical advice. Always talk to a doctor or pharmacist about your own situation.
Joint pain and swellingSkin plaquesFatigueNail changesMorning stiffnessBack pain
Causal effect of thyroid function on cortical brain structure: A two-sample Mendelian randomization study.
The causal relationship between variations in thyroid dysfunction and brain structure remains elusive. We intended to probe into this causal connection using a Mendelian randomization (MR) approach. Aggregated statistics from the genome-wide Association Study (GWAS) on Autoimmune thyroid dysfunction…
ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype.
Recent evidence implicates altered RNA editing and dysregulated type I IFN signaling in immune-mediated diseases, including psoriasis, although the underlying genetic mechanisms remain poorly defined. We investigated four unrelated multiplex families with early-onset plaque psoriasis, with or withou…
Long-term rheumatologic comorbidities in familial Mediterranean fever.
Familial Mediterranean fever (FMF) is characterized by pyrin inflammasome dysregulation and chronic subclinical inflammation. Whether FMF carries an increased long-term burden of rheumatologic and autoimmune inflammatory disease is unclear. We evaluated baseline and long-term occurrence of rheumatol…
Psychological Aspects of Rheumatic Diseases: Psychorheumatology in Clinical Practice.
Rheumatic diseases (RDs) significantly impact patients' physical, psychological, and social well-being, yet psychological dimensions remain inadequately addressed in routine clinical practice. In this commentary, we examine psychological manifestations and mental health comorbidities in RDs, such as…
Examining the role of dipeptidyl peptidase IV (DPPIV) in psoriatic disease.
Chemokine CXCL10 plays an important role in PsA, an inflammatory arthritis associated with psoriasis. CXCL10 is post-translationally regulated by dipeptidyl peptidase-4 (DPPIV). The objectives of this study were to measure levels of DPPIV, CXCL10 and DPPIV enzyme activity (EA) in patients with PsA,…
Cardiovascular risk goal attainment in the United States rheumatologic population.
Rheumatologic diseases are independently linked to premature cardiovascular (CV) events. The emerging field of cardio-rheumatology addresses the intersection of inflammation and accelerated atherosclerosis driving excess CV risk. Despite calls to action, data on risk factor optimization, antihyperli…
Who Achieves Minimal and Very Low Disease Activity in Psoriatic Arthritis? An Analysis of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
To evaluate the achievement of minimal disease activity (MDA) and very low disease activity (VLDA) in patients with psoriatic arthritis (PsA) treated in a real-world clinical setting with biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). This study included patients wit…
Ustekinumab for the treatment of psoriasis: a well-established therapy primed for resurgence.
Ustekinumab has been an approved biologic therapy for moderate-to-severe psoriasis for over 16 years. With the emergence of newer IL-17 and IL-23 inhibitors, its use was largely supplanted by these more effective treatments. With the introduction of biosimilars, ustekinumab's potential role in the c…